Breaking News, Promotions & Moves

Curi Bio Names Nicholas Geisse CEO

Geisse succeeds Michael Cho, J.D., who will continue with the company in a role focusing on corporate strategy and legal matters.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Curi Bio, a developer of human stem cell-based platforms for drug discovery, has appointed  Nicholas A. Geisse, Ph.D. as Chief Executive Officer, effective immediately. Dr. Geisse has been serving as the Chief Science Officer at Curi Bio since 2017. During that time, he was responsible for guiding the company’s scientific strategy and the commercialization of its next-generation products designed to greatly improve the predictive power of in vitro cell-based assays. Dr. Geisse succeeds Michael C...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters